New VP Sales & Marketing at ViroGates

Wed Mar 21 2018

We are delighted to introduce Thomas Krarup, who joins ViroGates as the Vice President of Sales and Marketing. With an extensive educational background, Thomas brings a wealth of knowledge and experience to our team. He holds a Ph.D. in biology from Copenhagen University in Denmark and Syracuse University in the USA, exemplifying his commitment to academic excellence.

Throughout his career, Thomas Krarup has made significant contributions to the life sciences sector. He has worked with industry leaders like Radiometer Medical, Becton Dickinson, and Roche, as well as dynamic roles at smaller companies like Exiqon and ChemoMetec. His responsibilities have encompassed scientific marketing, licensing, business development, and sales, showcasing his comprehensive grasp of the industry.

In the next phase, Thomas will play a crucial role in solidifying ViroGates’ market presence. His responsibilities include overseeing direct sales operations and managing the distributor network. With strategic insights and deep industry understanding, Thomas aims to propel ViroGates’ suPARnostic® biomarker into mainstream use within Emergency Departments. This biomarker equips medical professionals with a valuable tool for informed patient discharge decisions, promising enhanced patient care and substantial cost savings for hospitals.

Thomas Krarup’s enthusiasm for his new role is evident. “I am excited about the widespread adoption of the suPARnostic® biomarker in routine clinical use within Emergency Departments. This will aid doctors in making well-informed patient discharge decisions and contribute to significant cost savings for hospitals,” he shares. Aligned with the company’s objectives, Thomas is poised to make a meaningful impact on healthcare outcomes.

We warmly welcome Thomas Krarup and extend our best wishes for his new role. His expertise and dedication are set to contribute significantly to ViroGates’ growth trajectory, ultimately leading to improved healthcare solutions and enhanced patient experiences.


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPARnostic POC+


Point-of-care finger prick

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates